Businesswire11.26.19
AngioDynamics Inc., a provider of minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that Michael C. Greiner, executive vice president and chief financial officer (CFO) will be departing the company. Stephen A. Trowbridge, senior vice president and general counsel, will assume the role of interim CFO in addition to his current responsibilities.
Greiner will remain with AngioDynamics to facilitate a smooth transition of duties up to the filing of the second fiscal quarter 10-Q, and the company has initiated a process to determine a permanent successor.
“We have made meaningful progress since Michael joined AngioDynamics three years ago. We are a stronger company today, and Michael has played an integral role in the transformation of our portfolio, strengthening of our balance sheet and building a talented and capable finance and accounting team,” said Jim Clemmer, president and CEO of AngioDynamics Inc. “Completing the acquisition of Eximo Medical was a significant milestone that offered us an opportunity to reflect on the accomplishments of the past three years and evaluate our future. Michael and I mutually agreed that now is the right time to bring a new perspective to the organization as we enter our next phase of execution. On behalf of the Board of Directors and everyone at AngioDynamics, I want to thank Michael for all of his contributions, and we wish him and his family all the best.”
Greiner's departure is unrelated to AngioDynamics’ business performance, financial reporting, or controls.
The company is reaffirming its previously issued financial guidance for fiscal year 2020.
AngioDynamics Inc. is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ product lines include ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.
Greiner will remain with AngioDynamics to facilitate a smooth transition of duties up to the filing of the second fiscal quarter 10-Q, and the company has initiated a process to determine a permanent successor.
“We have made meaningful progress since Michael joined AngioDynamics three years ago. We are a stronger company today, and Michael has played an integral role in the transformation of our portfolio, strengthening of our balance sheet and building a talented and capable finance and accounting team,” said Jim Clemmer, president and CEO of AngioDynamics Inc. “Completing the acquisition of Eximo Medical was a significant milestone that offered us an opportunity to reflect on the accomplishments of the past three years and evaluate our future. Michael and I mutually agreed that now is the right time to bring a new perspective to the organization as we enter our next phase of execution. On behalf of the Board of Directors and everyone at AngioDynamics, I want to thank Michael for all of his contributions, and we wish him and his family all the best.”
Greiner's departure is unrelated to AngioDynamics’ business performance, financial reporting, or controls.
The company is reaffirming its previously issued financial guidance for fiscal year 2020.
AngioDynamics Inc. is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ product lines include ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.